Crestone Pharma
Share
11/21/2024
CRS3123 is a small molecule protein synthesis inhibitor that acts on the novel target methionyl-tRNA synthetase (MetRS). CRS3123 has numerous potential advantages over current CDI therapies.
Learn more about C. difficile Infection (CDI) and the Phase 2 study of CRS3123 here: https://bit.ly/3zhg5Kb
Want your practice to be the top-listed Clinic in Boulder?
Click here to claim your Sponsored Listing.
Click here to claim your Sponsored Listing.
Category
Telephone
Website
Address
Boulder, CO
80301
